Clinical spectrum of HTLV-I in South Florida

W. J. Harrington, A. Ucar, P. Gill, S. Snodgrass, William Sheremata, L. Cabral, M. Rabin, G. E. Byrne, J. Berger, W. Voight, R. Kemper, G. Miller, C. C. Whitcomb, A. Greenberg, John Byrnes, B. Poiesz

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

A total of 113 patients with infection due to human T-cell leukemia virus type 1 (HTLV-I) were evaluated at the University of Miami from January 1988 to March 1993. Forty patients were identified with adult T-cell leukemia/lymphoma (ATLL) and 63 with HTLV-I-associated myelopathy (HAM). Three had concomitant ATLL and HAM. Two HAM patients co-infected with human immunodeficiency virus type 1 (HIV-I) developed clonal lymphoproliferative disease during the study period. Patients with ATLL have a poor prognosis; multiple chemotherapy regimens including high-dose cytotoxic agents have been utilized with a small impact on survival. Most of our patients are currently treated with experimental regimens. Rheumatologic or autoimmune illnesses were identified, mostly in HAM patients, and a small number developed immunodeficiencies in the absence of other definable etiologic factors. Most of the patients were immigrants from areas of endemicity in the Caribbean basin, although many Americans were also recognized. HTLV-I/II infection was diagnosed serologically and typed as HTLV-I by polymerase chain reaction (PCR) or a modified Western blot when a DNA sample was not available. In 24 of 40 patients with ATLL, Southern blot hybridization performed on DNA extracted from peripheral blood lymphocytes or tumor tissue demonstrated clonal HTLV-I integration. In South Florida, ATLL and HAM are now seen frequently. Since HTLV-I infection is associated with a 4% lifetime risk of developing ATLL and an additional 0.25% lifetime risk for developing HAM, a large pool of asymptomatically infected individuals must exist here. Autoimmune conditions and immunodeficiency states are not uncommon in these patients. Unusual clinical presentations are now being recognized in those co-infected with HTLV-I and HIV-I.

Original languageEnglish
Pages (from-to)466-473
Number of pages8
JournalJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume8
Issue number5
StatePublished - Jan 1 1995

Fingerprint

Deltaretrovirus
Adult T Cell Leukemia Lymphoma
Tropical Spastic Paraparesis
HIV-1
Human T-lymphotropic virus 2
Virus Integration
Spinal Cord Diseases
DNA
Cytotoxins
Virus Diseases
Southern Blotting
Infection
Western Blotting
Lymphocytes
Drug Therapy
Polymerase Chain Reaction

Keywords

  • Adult T-cell leukemia/lymphoma (ATLL)
  • HIV-I
  • HTLV-I
  • HTLV-I-associated myelopathy (HAM)

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Immunology and Allergy

Cite this

Harrington, W. J., Ucar, A., Gill, P., Snodgrass, S., Sheremata, W., Cabral, L., ... Poiesz, B. (1995). Clinical spectrum of HTLV-I in South Florida. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 8(5), 466-473.

Clinical spectrum of HTLV-I in South Florida. / Harrington, W. J.; Ucar, A.; Gill, P.; Snodgrass, S.; Sheremata, William; Cabral, L.; Rabin, M.; Byrne, G. E.; Berger, J.; Voight, W.; Kemper, R.; Miller, G.; Whitcomb, C. C.; Greenberg, A.; Byrnes, John; Poiesz, B.

In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 8, No. 5, 01.01.1995, p. 466-473.

Research output: Contribution to journalArticle

Harrington, WJ, Ucar, A, Gill, P, Snodgrass, S, Sheremata, W, Cabral, L, Rabin, M, Byrne, GE, Berger, J, Voight, W, Kemper, R, Miller, G, Whitcomb, CC, Greenberg, A, Byrnes, J & Poiesz, B 1995, 'Clinical spectrum of HTLV-I in South Florida', Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 8, no. 5, pp. 466-473.
Harrington WJ, Ucar A, Gill P, Snodgrass S, Sheremata W, Cabral L et al. Clinical spectrum of HTLV-I in South Florida. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1995 Jan 1;8(5):466-473.
Harrington, W. J. ; Ucar, A. ; Gill, P. ; Snodgrass, S. ; Sheremata, William ; Cabral, L. ; Rabin, M. ; Byrne, G. E. ; Berger, J. ; Voight, W. ; Kemper, R. ; Miller, G. ; Whitcomb, C. C. ; Greenberg, A. ; Byrnes, John ; Poiesz, B. / Clinical spectrum of HTLV-I in South Florida. In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1995 ; Vol. 8, No. 5. pp. 466-473.
@article{03a5822811344657b2f9d5c5b88c765f,
title = "Clinical spectrum of HTLV-I in South Florida",
abstract = "A total of 113 patients with infection due to human T-cell leukemia virus type 1 (HTLV-I) were evaluated at the University of Miami from January 1988 to March 1993. Forty patients were identified with adult T-cell leukemia/lymphoma (ATLL) and 63 with HTLV-I-associated myelopathy (HAM). Three had concomitant ATLL and HAM. Two HAM patients co-infected with human immunodeficiency virus type 1 (HIV-I) developed clonal lymphoproliferative disease during the study period. Patients with ATLL have a poor prognosis; multiple chemotherapy regimens including high-dose cytotoxic agents have been utilized with a small impact on survival. Most of our patients are currently treated with experimental regimens. Rheumatologic or autoimmune illnesses were identified, mostly in HAM patients, and a small number developed immunodeficiencies in the absence of other definable etiologic factors. Most of the patients were immigrants from areas of endemicity in the Caribbean basin, although many Americans were also recognized. HTLV-I/II infection was diagnosed serologically and typed as HTLV-I by polymerase chain reaction (PCR) or a modified Western blot when a DNA sample was not available. In 24 of 40 patients with ATLL, Southern blot hybridization performed on DNA extracted from peripheral blood lymphocytes or tumor tissue demonstrated clonal HTLV-I integration. In South Florida, ATLL and HAM are now seen frequently. Since HTLV-I infection is associated with a 4{\%} lifetime risk of developing ATLL and an additional 0.25{\%} lifetime risk for developing HAM, a large pool of asymptomatically infected individuals must exist here. Autoimmune conditions and immunodeficiency states are not uncommon in these patients. Unusual clinical presentations are now being recognized in those co-infected with HTLV-I and HIV-I.",
keywords = "Adult T-cell leukemia/lymphoma (ATLL), HIV-I, HTLV-I, HTLV-I-associated myelopathy (HAM)",
author = "Harrington, {W. J.} and A. Ucar and P. Gill and S. Snodgrass and William Sheremata and L. Cabral and M. Rabin and Byrne, {G. E.} and J. Berger and W. Voight and R. Kemper and G. Miller and Whitcomb, {C. C.} and A. Greenberg and John Byrnes and B. Poiesz",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "8",
pages = "466--473",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "5",

}

TY - JOUR

T1 - Clinical spectrum of HTLV-I in South Florida

AU - Harrington, W. J.

AU - Ucar, A.

AU - Gill, P.

AU - Snodgrass, S.

AU - Sheremata, William

AU - Cabral, L.

AU - Rabin, M.

AU - Byrne, G. E.

AU - Berger, J.

AU - Voight, W.

AU - Kemper, R.

AU - Miller, G.

AU - Whitcomb, C. C.

AU - Greenberg, A.

AU - Byrnes, John

AU - Poiesz, B.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - A total of 113 patients with infection due to human T-cell leukemia virus type 1 (HTLV-I) were evaluated at the University of Miami from January 1988 to March 1993. Forty patients were identified with adult T-cell leukemia/lymphoma (ATLL) and 63 with HTLV-I-associated myelopathy (HAM). Three had concomitant ATLL and HAM. Two HAM patients co-infected with human immunodeficiency virus type 1 (HIV-I) developed clonal lymphoproliferative disease during the study period. Patients with ATLL have a poor prognosis; multiple chemotherapy regimens including high-dose cytotoxic agents have been utilized with a small impact on survival. Most of our patients are currently treated with experimental regimens. Rheumatologic or autoimmune illnesses were identified, mostly in HAM patients, and a small number developed immunodeficiencies in the absence of other definable etiologic factors. Most of the patients were immigrants from areas of endemicity in the Caribbean basin, although many Americans were also recognized. HTLV-I/II infection was diagnosed serologically and typed as HTLV-I by polymerase chain reaction (PCR) or a modified Western blot when a DNA sample was not available. In 24 of 40 patients with ATLL, Southern blot hybridization performed on DNA extracted from peripheral blood lymphocytes or tumor tissue demonstrated clonal HTLV-I integration. In South Florida, ATLL and HAM are now seen frequently. Since HTLV-I infection is associated with a 4% lifetime risk of developing ATLL and an additional 0.25% lifetime risk for developing HAM, a large pool of asymptomatically infected individuals must exist here. Autoimmune conditions and immunodeficiency states are not uncommon in these patients. Unusual clinical presentations are now being recognized in those co-infected with HTLV-I and HIV-I.

AB - A total of 113 patients with infection due to human T-cell leukemia virus type 1 (HTLV-I) were evaluated at the University of Miami from January 1988 to March 1993. Forty patients were identified with adult T-cell leukemia/lymphoma (ATLL) and 63 with HTLV-I-associated myelopathy (HAM). Three had concomitant ATLL and HAM. Two HAM patients co-infected with human immunodeficiency virus type 1 (HIV-I) developed clonal lymphoproliferative disease during the study period. Patients with ATLL have a poor prognosis; multiple chemotherapy regimens including high-dose cytotoxic agents have been utilized with a small impact on survival. Most of our patients are currently treated with experimental regimens. Rheumatologic or autoimmune illnesses were identified, mostly in HAM patients, and a small number developed immunodeficiencies in the absence of other definable etiologic factors. Most of the patients were immigrants from areas of endemicity in the Caribbean basin, although many Americans were also recognized. HTLV-I/II infection was diagnosed serologically and typed as HTLV-I by polymerase chain reaction (PCR) or a modified Western blot when a DNA sample was not available. In 24 of 40 patients with ATLL, Southern blot hybridization performed on DNA extracted from peripheral blood lymphocytes or tumor tissue demonstrated clonal HTLV-I integration. In South Florida, ATLL and HAM are now seen frequently. Since HTLV-I infection is associated with a 4% lifetime risk of developing ATLL and an additional 0.25% lifetime risk for developing HAM, a large pool of asymptomatically infected individuals must exist here. Autoimmune conditions and immunodeficiency states are not uncommon in these patients. Unusual clinical presentations are now being recognized in those co-infected with HTLV-I and HIV-I.

KW - Adult T-cell leukemia/lymphoma (ATLL)

KW - HIV-I

KW - HTLV-I

KW - HTLV-I-associated myelopathy (HAM)

UR - http://www.scopus.com/inward/record.url?scp=0028906940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028906940&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 466

EP - 473

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 5

ER -